Good company judging by the company's performance and stock trend. Rolled back to the area 30% on the news about the vaccine Quarterly reporting will be February 2, 2021. If vaccination does not show significant benefits and the company's revenues continue to grow, it is possible that the shares will be bought back.
What do you think about the shares of this company?
Trade active
⋅
Consolidation is broken upwards.
Comment
⋅
Option Finder:
Long Call: Buy 1x 15th Oct $590,00 Call @ $4,10 Entry cost: $410,00 (debit) Maximum risk1: $410,00 Est. return1 at target price: $3 590,00 (875.6%)